My name is Frederic Leduc. I'm the co-founder and chief business officer of Immune Biosolutions. At Immune Biosolutions, we strongly believe that biologists can transform and save lives. Leveraging our technology platforms, we hacked the immune system of chickens to discover and engineer the next generation of immunotherapies, infectious disease, and oncology. So for COVID-19, we actually parallelized a lot of different approaches to generate high-affinity antibodies. We immunized chickens and we also collected B-cells from convalescent patients. We used our technologies to find the right antibodies. And actually, at the end, we selected a group of three different antibodies with three different mode of action to neutralize the virus. The uniqueness of our approach is to basically address different ways to fight the virus, but also a very unique way to administer these antibodies, through inhalation. Because of the priming side of replication of virus to lungs, we think that by administering the antibodies directly in the lungs, we can neutralize it faster and better. So cytometry is really one of the technology, the methodology that we're using throughout the process of discovering development. From target validation up to even biomanufacturing to validate the antibodies, we're using that approach to validate the quality of the antibodies but also the specificity of those antibodies. We definitely use it to separate cells, unique samples that we have to validate. There are antibodies coming from tissue and other source, biological source, rare biological source, should I say. We also use it in our process of validation. We have rich libraries of antibodies that we want to validate their affinity, their specificity, so definitely cytometry is a really practical way to do that. In our work, we're using an SH800 Sony cytometer. It is really practical for our scientists for many reasons: on the analysis side, also with the cell sorting capacity, really practical in everything that we do. It is easy to set up. All of our scientists can operate this machine within a few minutes. It provides simple ways to do experiments and really clear-cut results. And that's essential for our work. Our scientists are putting all their efforts in the complexity of the biology, not the complexity of using a cytometer. It is as simple as we had a visit a few years back with a minister with no scientific background, and I was able to explain how this machine works but also explain the results of the experiments with a few click of the mouse. So really simple to operate and providing amazing results. The future of Immune Biosolutions is really to address the complexity of some of the disease. And we think by combining different technologies that we had available over the last few months with COVID-19, we will be able to address complexities in cancer, in inflammation, and definitely be able to generate a brand new generation of immunotherapies that will be able to address this complexity and save patients. That's always our main goal. So we think that using the lessons of COVID-19, we will be able to develop immunotherapies at pandemic pace. So that is critical for our work.
.png)
